Addition of DHA synergistically enhances the efficacy of regorafenib for kidney cancer therapy

Jeffrey Kim, Arzu Ulu, Debin Wan, Jun Yang, Bruce D. Hammock, Robert H Weiss

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Kidney cancer is the sixth most common cancer in the United States, and its incidence is increasing. The treatment of this malignancy took a major step forward with the recent introduction of targeted therapeutics, such as kinase inhibitors. Unfortunately, kinase inhibition is associated with the onset of resistance after 1 to 2 years of treatment. Regorafenib, like many multikinase inhibitors, was designed to block the activities of several key kinase pathways involved in oncogenesis (Ras/Raf/ MEK/ERK) and tumor angiogenesis (VEGF-receptors), and we have recently shown that it also possesses soluble epoxide hydrolase (sEH) inhibitory activity, which may be contributing to its salutary effects in patients. Because sEH inhibition results in increases in the DHA-derived epoxydocosapentaenoic acids that we have previously described to possess anticancer properties, we asked whether the addition of DHA to a therapeutic regimen in the presence of regorafenib would enhance its beneficial effects in vivo. We now show that the combination of regorafenib and DHA results in a synergistic effect upon tumor invasiveness as well as p-VEGFR attenuation. In addition, this combination showed a reduction in tumor weights, greater than each agent alone, in a mouse xenograft model of human renal cell carcinoma (RCC), yielding the expected oxylipin profiles; these data were supported in several RCC cell lines that showed similar results in vitro. Because DHA is the predominant component of fish oil, our data suggest that this nontoxic dietary supplement could be administered with regorafenib during therapy for advanced RCC and could be the basis of a clinical trial.

Original languageEnglish (US)
Pages (from-to)890-898
Number of pages9
JournalMolecular Cancer Therapeutics
Volume15
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Kidney Neoplasms
Renal Cell Carcinoma
Epoxide Hydrolases
Phosphotransferases
Neoplasms
Oxylipins
Therapeutics
Vascular Endothelial Growth Factor Receptor
Fish Oils
Mitogen-Activated Protein Kinase Kinases
Dietary Supplements
Tumor Burden
Heterografts
Carcinogenesis
regorafenib
Clinical Trials
Cell Line
Acids
Incidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Addition of DHA synergistically enhances the efficacy of regorafenib for kidney cancer therapy. / Kim, Jeffrey; Ulu, Arzu; Wan, Debin; Yang, Jun; Hammock, Bruce D.; Weiss, Robert H.

In: Molecular Cancer Therapeutics, Vol. 15, No. 5, 01.05.2016, p. 890-898.

Research output: Contribution to journalArticle

Kim, Jeffrey ; Ulu, Arzu ; Wan, Debin ; Yang, Jun ; Hammock, Bruce D. ; Weiss, Robert H. / Addition of DHA synergistically enhances the efficacy of regorafenib for kidney cancer therapy. In: Molecular Cancer Therapeutics. 2016 ; Vol. 15, No. 5. pp. 890-898.
@article{6ce987fff52c44ae9841b8a504603e26,
title = "Addition of DHA synergistically enhances the efficacy of regorafenib for kidney cancer therapy",
abstract = "Kidney cancer is the sixth most common cancer in the United States, and its incidence is increasing. The treatment of this malignancy took a major step forward with the recent introduction of targeted therapeutics, such as kinase inhibitors. Unfortunately, kinase inhibition is associated with the onset of resistance after 1 to 2 years of treatment. Regorafenib, like many multikinase inhibitors, was designed to block the activities of several key kinase pathways involved in oncogenesis (Ras/Raf/ MEK/ERK) and tumor angiogenesis (VEGF-receptors), and we have recently shown that it also possesses soluble epoxide hydrolase (sEH) inhibitory activity, which may be contributing to its salutary effects in patients. Because sEH inhibition results in increases in the DHA-derived epoxydocosapentaenoic acids that we have previously described to possess anticancer properties, we asked whether the addition of DHA to a therapeutic regimen in the presence of regorafenib would enhance its beneficial effects in vivo. We now show that the combination of regorafenib and DHA results in a synergistic effect upon tumor invasiveness as well as p-VEGFR attenuation. In addition, this combination showed a reduction in tumor weights, greater than each agent alone, in a mouse xenograft model of human renal cell carcinoma (RCC), yielding the expected oxylipin profiles; these data were supported in several RCC cell lines that showed similar results in vitro. Because DHA is the predominant component of fish oil, our data suggest that this nontoxic dietary supplement could be administered with regorafenib during therapy for advanced RCC and could be the basis of a clinical trial.",
author = "Jeffrey Kim and Arzu Ulu and Debin Wan and Jun Yang and Hammock, {Bruce D.} and Weiss, {Robert H}",
year = "2016",
month = "5",
day = "1",
doi = "10.1158/1535-7163.MCT-15-0847",
language = "English (US)",
volume = "15",
pages = "890--898",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Addition of DHA synergistically enhances the efficacy of regorafenib for kidney cancer therapy

AU - Kim, Jeffrey

AU - Ulu, Arzu

AU - Wan, Debin

AU - Yang, Jun

AU - Hammock, Bruce D.

AU - Weiss, Robert H

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Kidney cancer is the sixth most common cancer in the United States, and its incidence is increasing. The treatment of this malignancy took a major step forward with the recent introduction of targeted therapeutics, such as kinase inhibitors. Unfortunately, kinase inhibition is associated with the onset of resistance after 1 to 2 years of treatment. Regorafenib, like many multikinase inhibitors, was designed to block the activities of several key kinase pathways involved in oncogenesis (Ras/Raf/ MEK/ERK) and tumor angiogenesis (VEGF-receptors), and we have recently shown that it also possesses soluble epoxide hydrolase (sEH) inhibitory activity, which may be contributing to its salutary effects in patients. Because sEH inhibition results in increases in the DHA-derived epoxydocosapentaenoic acids that we have previously described to possess anticancer properties, we asked whether the addition of DHA to a therapeutic regimen in the presence of regorafenib would enhance its beneficial effects in vivo. We now show that the combination of regorafenib and DHA results in a synergistic effect upon tumor invasiveness as well as p-VEGFR attenuation. In addition, this combination showed a reduction in tumor weights, greater than each agent alone, in a mouse xenograft model of human renal cell carcinoma (RCC), yielding the expected oxylipin profiles; these data were supported in several RCC cell lines that showed similar results in vitro. Because DHA is the predominant component of fish oil, our data suggest that this nontoxic dietary supplement could be administered with regorafenib during therapy for advanced RCC and could be the basis of a clinical trial.

AB - Kidney cancer is the sixth most common cancer in the United States, and its incidence is increasing. The treatment of this malignancy took a major step forward with the recent introduction of targeted therapeutics, such as kinase inhibitors. Unfortunately, kinase inhibition is associated with the onset of resistance after 1 to 2 years of treatment. Regorafenib, like many multikinase inhibitors, was designed to block the activities of several key kinase pathways involved in oncogenesis (Ras/Raf/ MEK/ERK) and tumor angiogenesis (VEGF-receptors), and we have recently shown that it also possesses soluble epoxide hydrolase (sEH) inhibitory activity, which may be contributing to its salutary effects in patients. Because sEH inhibition results in increases in the DHA-derived epoxydocosapentaenoic acids that we have previously described to possess anticancer properties, we asked whether the addition of DHA to a therapeutic regimen in the presence of regorafenib would enhance its beneficial effects in vivo. We now show that the combination of regorafenib and DHA results in a synergistic effect upon tumor invasiveness as well as p-VEGFR attenuation. In addition, this combination showed a reduction in tumor weights, greater than each agent alone, in a mouse xenograft model of human renal cell carcinoma (RCC), yielding the expected oxylipin profiles; these data were supported in several RCC cell lines that showed similar results in vitro. Because DHA is the predominant component of fish oil, our data suggest that this nontoxic dietary supplement could be administered with regorafenib during therapy for advanced RCC and could be the basis of a clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=84964450132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964450132&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-15-0847

DO - 10.1158/1535-7163.MCT-15-0847

M3 - Article

VL - 15

SP - 890

EP - 898

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -